Amgen's proactive international expansion, promising late-stage pipeline, and strong Q4 performance instill confidence. The pending PCSK9 inhibitor, evolocumab, has posted positive Phase III results, positioning Amgen for a 2014 global filing. However, reliance on Kaitlyn rebounded refractory multiple myeloma drugs and biosimilars launching in 2017 adds caution. The stock is likely to consolidate in the short term, awaiting further pipeline and market share developments.
[0]